FDA: 2×2×4 design; RSABE + ABE + σwT/σwR [Design Issues]

posted by Pharma_88 – India, 2020-03-13 09:14 (880 d 05:08 ago) – Posting: # 21262
Views: 2,976

» All of the product-specific guidances contain a section ‘Explanation’. See also Yu et al.

OK

» » Further, can we perform crossover studies for NTI by taking extra safety measurement in to the study?
»
» You can. Whether that is necessary in healthy volunteers depends on the drug.

Yes.

» » Further, what is the BE limit for such drugs?
»
» It depends on \(\small{s_{wR}}\) observed in the study, i.e., reference-scaling is applied. Furthermore – irrespective of passing the scaled limits – the study has to pass 80.00–125.00% as well and the upper confidence limit of \(\small{\sigma_{wT}/\sigma_{wR}}\) has to be ≤2.5.

its common for all NTI or its varies from drug to drug?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,290 posts in 4,666 threads, 1,584 registered users;
online 8 (2 registered, 6 guests [including 4 identified bots]).
Forum time: Wednesday 15:22 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5